News & Media

    Charleston Laboratories, Inc. Reacquires Rights to Novel Investigational Treatment CL-108, for Acute Pain and Opioid-Induced Nausea and Vomiting
    Charleston Laboratories, Inc. Announces Senior Global Regulatory Hire
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use
    Charleston Laboratories, Inc. Announces Formation of U.S. Commercial Subsidiary
    Charleston Laboratories, Inc. Expands Senior Management Team with Two Key Appointments in Core Business Areas of Medical & Commercialization
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108
    Charleston Laboratories, Inc. Announces Presentations at the Annual Scientific Meeting of the American Pain Society
    Governor Scott Announces Charleston Laboratories, Inc. Expansion Will Create 25 New Jobs
    The Business Development Board of Palm Beach Plays Key Role in Charleston Laboratories, Inc. Expansion
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Phase 3 Study of CL-108 Met Primary Endpoints
    Charleston Laboratories, Inc. Announces Completion of a Second Phase 3 Clinical Trial on its Lead Product, CL-108, and the Appointment of Dr. Raymond Dionne to its Scientific Advisory Board
    Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston’s Second Product, CL-H1T
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce Three Poster Presentations at American Pain Society Annual Meeting
    Charleston Laboratories, Inc. Completes Patient Enrollment in a Phase 3
    Charleston Laboratories, Inc. & Daiichi Sankyo, Inc. Announce Completion of a Pharmacokinetics Study on CL-108
    Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Initiate Two Phase 3 Clinical Trials on Charleston’s Lead Product, CL-108
    Prescription for Success
    Charleston Laboratories, Inc. Announces Key Clinical Updates for Novel Drugs
    Charleston Laboratories and Daiichi Sankyo Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US
    Charleston Laboratories, Inc., Bolsters Senior Management Team
    Charleston Laboratories, Inc. Announces Publication of Abstract for CL-108 Phase 3 Study at APS 2014
    Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
    Charleston Laboratories, Inc. Announces Research Collaboration with Stanford University
    Charleston Laboratories, Inc Successfully Completes Pre-IND Meeting on New Migraine Treatment
    FDA Grants Charleston Laboratories, Inc. Request for Pre-IND Meeting on New Migraine Treatment
    Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
    Charleston Laboratories, Inc. Awarded a Qualifying Therapeutic Discovery Project Grant
    Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108
    Charleston Conducts Evaluation of an Opioid Symptoms Questionnaire
    Charleston Completes Preliminary Research on Nausea-Prone Questionnaire (NPQ)
    Charleston Labs begins Bioequivalence Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CL-108
    Charleston completes successful Type B, Pre-IND meeting with FDA’s Division of Anesthesia, Analgesia and Rheumatology Products on November 8, 2007, held at FDA’s Silver Spring, Maryland offices.